Neuraptive Therapeutics is developing and commercializing novel nerve repair technologies centered on its flagship product, the AxoFuse Nerve Repair System (AxoFuse™). AxoFuse is a therapeutic product intended for use in conjunction with standard nerve repair surgery to improve outcomes for patients with peripheral nerve injuries. The company plans to use Series A proceeds to further develop AxoFuse in clinical trials and to expand operations. Clinical trials for AxoFuse were anticipated to begin in 2019. Led by CEO and co-founder David Jackson, Neuraptive was established to improve clinical outcomes for patients and the surgeons who care for them. The company is based in Lafayette, Colorado and Philadelphia, Pennsylvania.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2018